Brexit Transfers Nearly Complete But EMA Staff & Resource Pressures Remain
Executive Summary
Practically all centralized marketing authorizations held in the UK have now been moved to the EU, but Brexit and the European Medicines Agency’s relocation to Amsterdam are still causing the EMA some staffing and resource headaches.
You may also be interested in...
EMA Under Pressure Again As Staff Losses Worsen
Higher than expected staff losses due to the relocation to Amsterdam are posing challenges for the European Medicines Agency as it prepares to implement new EU legislation, and it is having to further prioritize its business activities. But the agency's planned move to a permanent HQ in the Dutch capital is still on track.
EU Urges Regulatory Compliance As UK Flounders In Brexit Chaos
The European Commission says more needs to be done to ensure that all authorized medicines are in compliance with the regulations ahead of Brexit. Meanwhile, machinations in the UK parliament have cast doubt over whether the UK will actually leave the EU at the end of October.
Brexit Relief For Pharma As EMA Grants Most Batch Testing Exemptions
Of the 60 or so applications the European Medicine Agency has received from drug companies hoping for more time to move their batch testing sites from the UK to the EU, about 50 have been successful.